Biotech Startups

Acquired by Shire in 2014 (now part of Takeda).

6 investors

Mahzi develops therapies for patients with under-diagnosed and under-served rare genetic neurodevelopmental disorders, working with patient and family groups, academic researchers, and industry partners. The company operates across biopharmaceutical research, development, and manufacturing.

6 investors

Maze Therapeutics develops precision medicines for common diseases with high unmet need, using its Compass platform based on human genetics and variant functionalization. Its pipeline focuses on kidney disease, including programs for APOL1-mediated kidney disease, chronic kidney disease, and phenylketonuria.

6 investors

MBX Biosciences is a clinical-stage biopharmaceutical company developing peptide therapeutics for endocrine and metabolic diseases. It applies expertise in peptide discovery and development to create precision peptide medicines aimed at improving treatment standards for these conditions.

6 investors

MeliBio is a California-based biotech company that develops plant-based honey alternatives using proprietary plant-science technology to replace commercial honeybees, addressing food security and supply chain challenges while supporting native pollinator biodiversity.

6 investors

Melio develops a rapid bloodborne pathogen testing platform that identifies common pathogens from blood samples within hours, replacing traditional multi-day culture-based diagnostics.

6 investors

MeMed develops a rapid 15-minute diagnostic test using machine learning to distinguish bacterial from viral infections by analyzing immune system biomarkers. The test serves physicians and hospitals to reduce inappropriate antibiotic prescriptions and improve patient outcomes in acute infection management.

6 investors

Metcela is a Japanese biotech company developing science-backed therapies for pediatric and rare diseases, with in-house capabilities spanning research through development. Its work builds on regenerative medicine and cardiac stem cell development expertise.

6 investors

Miracle unifies data from multiple clinical trial platforms to provide automated insights for healthcare professionals in biopharma. The company aims to accelerate clinical trial execution and help bring new therapeutics to market more efficiently.

6 investors

miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions. The company has advanced candidates in clinical testing and is preparing commercial infrastructure for potential product launches.

6 investors

miRecule is a biotechnology company developing therapeutics, with programs focused on oncology. It applies RNA-based drug development approaches within the biotech industry.

6 investors

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments. The company is founded on research from Stanford University scientists and is led by experienced biopharmaceutical industry executives.

6 investors

Mozza Foods develops casein protein grown in soybeans as an ingredient for the dairy industry, aiming to replace cow-dependent supply chains using existing agricultural infrastructure. The company targets dairy manufacturers with a bioengineered protein ingredient.

6 investors

Multus designs cell culture media for the industrial bioeconomy, applying AI, robotics, and biological expertise to media formulation. It serves biomanufacturing companies producing cell-based therapies, food, and materials, aiming to reduce their time to market and improve supply chain and unit economics.

6 investors

Nanochon develops Chondrograft, a 3D-printed, off-the-shelf orthopedic implant that is press-fit into damaged knee cartilage to support the body's natural tissue healing. It targets "pre-replacement" patients with focal cartilage defects who need more than temporary relief but are not yet candidates for joint replacement.

6 investors

Nanome provides a conversational, AI-assisted platform for exploring molecular structures across web and XR, letting researchers load, build, edit, and score structures using natural language and 300+ scientific tools. It is aimed at pharmaceutical and chemistry R&D teams working with 3D molecular data.

6 investors

Nanopath is developing a molecular diagnostic platform for point-of-care disease diagnosis, with a focus on women's health. The company builds novel diagnostic technologies aimed at scalable, accessible testing.

6 investors

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications. The company works with academic founders and institutional investors focused on advancing gene therapy treatments.

6 investors

Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease. It aims to match patient subsets defined by genetic drivers with targeted therapies for conditions such as Parkinson's and Alzheimer's.

6 investors

NoBACZ Healthcare develops antibiotic-free, patented liquid barrier products for wound and lesion management, creating waterproof physical barriers that block microbes as an alternative to topical antimicrobials. Its biodegradable formulas target animal health applications such as protecting hooves, horn buds and udders in farm environments, with active research collaborations with universities.

6 investors

Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves. The company is advancing taplucainium inhalation powder, a first-in-class therapy in Phase 2b clinical development for refractory and unexplained chronic cough, with potential applications in pain, itch, and other conditions driven by neurogenic inflammation.

6 investors

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance. The company builds its drug discovery pipeline through a partnership with the Lieping Chen lab at Yale School of Medicine, focusing on solid tumors.

6 investors

NRG Therapeutics is a biotech company developing small-molecule drugs targeting the mitochondrial permeability transition pore (mPTP) for neurodegenerative diseases such as ALS and Parkinson's. Its team combines pharma and biotech drug discovery expertise across neurology and neuroscience.

6 investors

Octave develops blood-based biomarker tests for neurodegenerative diseases including multiple sclerosis, Parkinson's disease, and Alzheimer's disease. The company's tests enable physicians and patients to measure disease progression and treatment response through blood draws rather than traditional clinical assessments.

6 investors